ERBB2 and breast cancer: Inhibition of the EGFR in Her2 amplified breast cancer cells induces a reduction of PTPIP51 phosphorylation at the Tyr176 residue accompanied by a formation of the Raf-1/14-3-3β/PTPIP51 interactome, thus proofing a normal regulation of MAPK-related interactions of PTPIP51 [50].